Evaxion A/S
Evaxion A/S is a clinical-stage biotech company focused on developing vaccines and other drug candidates using its AI-Immunology™ platform. The company is based in Copenhagen, Denmark and operates as a research-driven developer of immunology-based therapeutics for infectious disease, cancer, and autoimmune applications.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueAI-based discovery tools used to identify immune targets and design candidates.
Therapeutic vaccine candidates aimed at oncology indications such as AML.
Vaccine development programs for infectious disease targets including polio-related work.
Research programs applying the platform to autoimmune disease targets.
Collaborative research activity and grant-supported development work.
Customers
Evaxion's direct customers are typically pharmaceutical, biotechnology, and research partners that license, fund, or collaborate on vaccine and immunology programs. It also depends on grant providers and public-interest funders for selected research projects, while future commercial demand would come from healthcare partners and developers seeking novel therapeutic candidates.
License or co-develop vaccine and drug candidates discovered through the platform.
Work with Evaxion on early-stage programs and platform validation.
Fund specific public-health research projects such as vaccine design work.
Use Evaxion's AI-enabled discovery approach for translational immunology work.
Strategy
Evaxion's strategy centers on advancing its AI-Immunology™ platform to generate differentiated vaccine and immunology candidates across multiple disease areas. It also emphasizes external validation through partners, investors, and research collaborations to broaden awareness of the platform and support program progression.
Progressing candidates is required to create value from the discovery platform.
External proof points improve credibility with partners and investors.
Applying the platform across multiple indications increases optionality.
Geography
Evaxion is headquartered in Copenhagen, Denmark, but its equity listing and investor base are international. The business is research-led and therefore relies more on partner networks, grants, and clinical collaboration channels than on physical manufacturing footprint.
Risks
Evaxion faces typical clinical-stage biotech risks: programs may fail in preclinical or clinical testing, timelines can extend materially, and value depends on successfully advancing a small number of assets. The company also carries liquidity, foreign exchange, and valuation-estimate risk because it has limited recognized revenue and relies on funding, grants, collaborations, and equity-linked instruments.
- Liquidity riskImpact: HighLikelihood: High
The company has not recognized meaningful revenue and depends on external funding.
Exposure: Operating cash needs and ongoing R&D
- Program failure in preclinical or clinical developmentImpact: HighLikelihood: Medium
Value depends on a small pipeline advancing successfully through testing.
Exposure: Therapeutic vaccines and AI-discovered candidates
- Warrant and share-based compensation volatilityImpact: MediumLikelihood: High
Equity-linked instruments and stock compensation can move reported expenses and liabilities.
Exposure: Derivative liability and employee incentives
- Foreign exchange riskImpact: MediumLikelihood: Medium
International collaboration and reporting can create currency mismatches.
Exposure
Accounting
Judgemental itemsRevenue may be limited to grants or collaboration-related amounts and depends on contract terms.
Impact: Affects comparability because revenue can be intermittent or nominal
Clinical-stage companies often rely on financing to continue operations.
Impact: Can influence disclosures and investor assessment of funding runway
Liability-classified warrants are measured at fair value and can reprice each period.
Impact: May create non-cash gains or losses in the income statement
Employee and management incentives are a material operating expense item.
Impact: Raises reported R&D and G&A expense without cash outflow
Similar listed companies
Publicly listed companies with a comparable business focus.
Genmab A/S
GMAB · Pharmaceutical Preparations
Genmab A/S is a Denmark-based biotechnology company focused on discovering and developing antibody medicines for cancer and other serious diseases.
Silexion Therapeutics Corp
SLXNW · Biological Products, (No Diagnostic Substances)
Silexion Therapeutics Corp is a U.S.-listed holding company whose operations are conducted primarily through its subsidiary Silexion, a clinical-stage…
Evogene Ltd.
EVGN · Agricultural Chemicals
Pyxis Oncology, Inc.
PYXS · Pharmaceutical Preparations
Janux Therapeutics, Inc.
JANX · Pharmaceutical Preparations
Janux Therapeutics is a clinical-stage biopharmaceutical company developing cancer immunotherapies built on its proprietary TRACTr, TRACIr, and ARM platforms.
ALX Oncology Holdings Inc
ALXO · Pharmaceutical Preparations
ALX Oncology Holdings Inc is a clinical-stage biotechnology company developing immuno-oncology therapies for cancer, headquartered in South San Francisco, California.
Last updated: 28/09/2026